Miranda Schmalfuhs

Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro's platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, which are effective against solid tumors. Abpro's lead oncology program for breast cancer, in partnership with Celltrion, is advancing through clinical phases. Additionally, they have an eye care molecule targeting AMD and DME. The recent NASDAQ listing will aid in accelerating R&D and commercialization efforts. Collaborations, like the one with Celltrion, have been instrumental in the company's success.

Many Aging Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses, That Combat Exposure May Make More Likely, New Research Finds

Two groundbreaking studies shed light on combat’s lasting physical and psychological damage more than 50 years on.

AI Data Center With Up to 3 Gigawatts of Power Is Envisioned for South Korea

Few global facilities possess more than a gigawatt of power, making electricity for AI computing increasingly scarce.

Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

Hims & Hers Health, Inc. plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making.

How will tariffs and federal funding shifts impact the pharmaceutical industry? Lowenstein FDA Regulatory Chair Jim Shehan continues his conversation with 

, discussing the potential ripple effects on drug prices and NIH-funded research.

Watch the full interview: 


Read Jim’s bio: https://lnkd.in/dfVXMGeP

#fda #drugprices #pharmaindustry #pharmaceuticals #foodanddrug

Have news you want us to share in Pharma Pulse? Reach out to Editor 

Articles

The latest news for pharma industry insiders.

Pharma Pulse 2/21/25: Challenges in Developing T Cell Engagers, Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses & more

Global Launch Strategies in the Current Political Climate

James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions.

Pharmacists Help Patients Navigate Vaccine Schedules

Many patients may struggle to understand the complex immunization schedules compiled by the CDC.

How AI Can Protect Vital Pipelines and Cables Deep in the Ocean

Militaries and startups use artificial intelligence to sift through vast amounts of data and power autonomous underwater vehicles, boosting efforts to surveil the seabed.

Rap Icon Nelly Joins the Kinexions 2025 Lineup

Kinaxis® announced that Nelly will be headlining the entertainment stage at Kinexions 2025, its annual supply chain community conference taking place in Austin, Texas from March 31 to April 2.

CEO James Foster shares insights on navigating global launch strategies amid political uncertainty. From adapting to tariffs to leveraging AI tools like ChatGPT for research, we’re staying nimble and ahead of the game.

Check out the interview with 



#vrax #Biotech #Innovation #Leadership #GlobalStrategy #AI

Pharma Pulse 2/20/25: Global Launch Strategies in the Current Political Climate, Pharmacists Help Navigate Vaccine Schedules & more

Navigating Distrust: Pharma in the Age of Social Media

Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.

Rising Demand for GLP-1 Receptor Agonists Means an Increase in Patient Questions

Pharmacists should emphasize the importance of medication adherence and lifestyle changes.

New York State Bans DeepSeek From Government Devices

New York state banned the use of DeepSeek on government devices, citing concerns over data privacy and censorship in the popular generative artificial intelligence app from China.

DeepSeek, owned by Chinese hedge fund High-Flyer, shot to fame in January, with its low-cost AI models rivaling American ones using less-advanced Nvidia chips.

Continues Longstanding Commitment to Heart Health Education,

Encouraging Americans to “See Their Risks”

In the United States alone, 104 million people are at risk of cardiovascular disease, and in a study of those that experienced a heart attack at age 50 or younger, half were not previously seen as high risk. This February, Bayer

 Aspirin is marking Heart Health Month with a new initiative to raise awareness and education about cardiovascular risk factors — especially among those who may dismiss the connection between age and heart health — and empower people to take proactive steps toward protecting their heart health by speaking with their healthcare provider about their risk factors.

Regulatory evolution is key as AI transforms pharmaceutical development.
At ApprovalFlow, we see firsthand how streamlined approvals help pharma teams stay agile and compliant in this shifting landscape.
Looking forward to these insights!
#RegulatoryInnovation #PharmaDevelopment #AIinPharma

Pharma Pulse 2/19/25: Pharma in the Age of Social Media, Rising Demand for GLP-1 Receptor Agonists Means More Questions & more

2025 Pipeline Report: The Edge of Greatness?

The biopharmaceutical industry has long been at the forefront of innovation. From the rise of precision medicine, to artificial intelligence technologies accelerating drug development, to the advent of small-molecule drugs, recent revolutions in pharmaceuticals are delivering better results for patients and more options for drug manufacturers.

Now, emerging developments in antibody-drug conjugates (ADCs) for oncology; hopeful treatments on the rise for idiopathic pulmonary fibrosis (IPF), a long-elusive disease to target; the transforming—and overarching—promise of GLP-1 agonists; growing investment around advanced therapy medicinal products (ATMPs); and a concerted push for new approaches in antibiotics are challenging the boundaries of what’s possible.

’s 20th Annual Pipeline Report profiles the most promising activity and efforts in development across these five therapeutic areas.

Patient Journey and the Role of the Pharmacist

Panelists discuss how the TD patient journey often begins with subtle symptoms that may go unrecognized, particularly in older adults who face unique challenges with diagnosis and treatment, while emphasizing the crucial role pharmacists play in early identification through medication reviews, regular monitoring of patients on antipsychotics, coordination with healthcare providers, and ongoing assessment of treatment response and adherence.

Irish Exports Hit Record in 2024 on Medical, Pharma Goods

Irish exports hit a record level in 2024, according to new data, largely driven by a boost in medical and pharmaceutical products being sent abroad.

New ‘Super Test’ for Prostate Cancer Developed in the UK by EDX Medical

Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionize screening and diagnosis of the disease and accelerate personalized treatment for patients.

The test identifies the presence or absence of cancerous cells, signs of early and late-stage cancer, whether it is slow or aggressive as well as genetic and hereditary risks in the patient. It also involves studying the most comprehensive combination of clinically-validated prostate-related biomarkers currently known, in both blood and urine samples. The interpretation of these biomarkers using a proprietary AI-driven algorithm highlights early signs of cancer and characteristic features that can guide treatment selection.

 is fresh off revealing its choices for the 15 latest drugs to be covered under Part D for price negotiations. Headlining that list is Ozempic, 

's branded semaglutide—which is a type of glucagon-like peptide-1 (GLP-1) receptor agonist. In my editor's note for the Feb issue of 

, I dug a little deeper into the drug class phenomenon that reveals some interesting takeaways on a smaller subgroup of users.